ReviewFEBS letters2011
Dissecting DNA hypermethylation in cancer.
Review in FEBS letters, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed, 1 synthesis or guideline pooled it, 87 citations in OpenAlex.
- Pooled it
- Fibroblast growth factor receptor inhibition for succinate dehydrogenase-deficient gastrointestinal stromal tumors: a phase 2 trial.Nature medicine · 2026Trial
- Epigenetic regulation of nephrogenesis: from Waddington's landscape to adult disease.American journal of physiology. Renal physiology · 2026Review
- Crosstalk along the gut-liver axis modulates glutathione and cadmium-induced hepatotoxicity.Frontiers in immunology · 2026Review
- Article
- Exportin 4 DNA promoter methylation in liver fibrosis.PloS one · 2024Article
- Non-pathogenic microbiota accelerate age-related CpG Island methylation in colonic mucosa.Epigenetics · 2023Article
- Implications of Cellular Mechanical Memory in Bioengineering.ACS biomaterials science & engineering · 2023Review
- Article
- Systematic pan-cancer analysis identifiesAnnals of translational medicine · 2023Article
- Mechanisms of myeloid leukemogenesis: Current perspectives and therapeutic objectives.Blood reviews · 2023Review
- Tracing the Origin of Cell-Free DNA Molecules through Tissue-Specific Epigenetic Signatures.Diagnostics (Basel, Switzerland) · 2022Review
- Epigenetic Changes and Functions in Pneumoconiosis.Oxidative medicine and cellular longevity · 2022Review
- A pan-cancer analysis revealing the role of TIGIT in tumor microenvironment.Scientific reports · 2021Article
- Adenosine kinase: An epigenetic modulator in development and disease.Neurochemistry international · 2021Review
- Small-Molecule Inhibitors Overcome Epigenetic Reprogramming for Cancer Therapy.Frontiers in pharmacology · 2021Review
- DNA Methylation Regulator-Meditated Modification Patterns Define the Distinct Tumor Microenvironment in Lung Adenocarcinoma.Frontiers in oncology · 2021Article
- Review
- Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.Frontiers in immunology · 2020Review
- DNA methylation patterns in bladder tumors of African American patients point to distinct alterations in xenobiotic metabolism.Carcinogenesis · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
There is compelling evidence to support the importance of DNA methylation alterations in cancer development. Both losses and gains of DNA methylation are observed, thought to contribute pathophysiologically by inactivating tumor suppressor genes, inducing chromosomal instability and ectopically activating gene expression. Lesser known are the causes of aberrant DNA methylation. Recent studies have pointed out that intrinsic gene susceptibility to DNA methylation, environmental factors and gene function all have an intertwined participation in this process. Overall, these data support a deterministic rather than a stochastic mechanism for de novo DNA methylation in cancer. In this review article, we discuss the technologies available to study DNA methylation and the endogenous and exogenous factors that influence the onset of de novo methylation in cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.